Lab & Scan
Search

Draft · no prices

Direct-to-consumer lab testing rules by state

Current as of Oct 19, 2026. No medical reviewer.

A state-by-state status list. New York has a cited laboratory rule. Every other state is marked Verify: pending.

How to read this list

Direct access means a laboratory accepts a request that did not start with the patient's own clinician. Rules differ by state, by test, and by seller. This page records a rule only when a statute or a regulator page was checked.

On this page, only New York has a regulator citation. Every other state and the District of Columbia stay at Verify: pending.

The FDA publishes an overview of direct-to-consumer tests. That page names the category. It is not a state statute, and this guide does not turn it into a permission to order a test.

A 2026 New York Senate bill, S9172, was introduced and would address direct access for specified lipid assays. It is not treated as law here. Verify: pending.

New York, as cited

Title 10 of the New York codes, section 58-1.7, says a clinical laboratory shall examine specimens only at the request of licensed physicians or other persons authorized by law, except as provided in section 58-1.9. This page does not summarize the 58-1.9 exception.

Section 58-1.8 says results of a test are reported only to a physician or other authorized person. A separate patient-access rule, 34-2.11, is named in the regulator's materials and is not restated here.

Seller availability for a given product is a different fact. This site's price pages say when a state note was not recorded.

States

Fifty states and the District of Columbia. A row without a statute or regulator link says Verify: pending.

Sources

  1. 10 NYCRR 58-1.7, Collection and acceptance of specimensAccessed
  2. 10 NYCRR 58-1.8, Results of tests to be reported only to physicians or other authorized personsAccessed
  3. New York Senate bill S9172 (2026), introduced, not treated as law on this pageAccessed
  4. FDA: Direct-to-consumer testsAccessed